New Med Research

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease3 trials

Phase

• Phase 32 trials
• Phase 2/31 trial

Status

• Recruiting2 trials
• Enrolling by invitation1 trial

Lead sponsor

• ACADIA Pharmaceuticals Inc.2 trials
• Karuna Therapeutics, Inc., a Bristol Myers Squibb company1 trial

Running trials

• Enrolling by invitation

  ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

  NCT06194799· Phase 3· ACADIA Pharmaceuticals Inc.· Source

• Recruiting

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· Phase 2/3· ACADIA Pharmaceuticals Inc.· Source

  Contact: Christine Murphy

• Recruiting

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

  Contact: Marta Fernandez, Site 1126

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease3 recruiting